These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B; BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634 [TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. Scheufele F; Friess H Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916 [TBL] [Abstract][Full Text] [Related]
13. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Hintz B; Lee VJ JAMA Oncol; 2023 Feb; 9(2):277. PubMed ID: 36454584 [No Abstract] [Full Text] [Related]
15. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Grossberg AJ; Jethwa KR; Ellsworth SG JAMA Oncol; 2023 Feb; 9(2):275. PubMed ID: 36454560 [No Abstract] [Full Text] [Related]
16. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Dincer N; Ugurluer G; Ozyar E JAMA Oncol; 2023 Feb; 9(2):276-277. PubMed ID: 36454557 [No Abstract] [Full Text] [Related]
17. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Hall WA; Evans DB; Tsai S JAMA Oncol; 2023 Feb; 9(2):275-276. PubMed ID: 36454556 [No Abstract] [Full Text] [Related]
18. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply. Katz MHG; Herman JM; O'Reilly EM JAMA Oncol; 2023 Feb; 9(2):277-278. PubMed ID: 36454565 [No Abstract] [Full Text] [Related]
19. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238 [TBL] [Abstract][Full Text] [Related]
20. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]